LEGEND BIOTECH CORP
NASDAQ: LEGN (Legend Biotech Corporation)
Kemas kini terakhir: semalam, 9:38AM23.59
0.07 (0.30%)
| Penutupan Terdahulu | 23.52 |
| Buka | 23.41 |
| Jumlah Dagangan | 995,865 |
| Purata Dagangan (3B) | 1,993,456 |
| Modal Pasaran | 4,363,103,744 |
| Harga / Pendapatan (P/E Ke hadapan) | 112.36 |
| Harga / Jualan (P/S) | 4.21 |
| Harga / Buku (P/B) | 4.34 |
| Julat 52 Minggu | |
| Tarikh Pendapatan | 12 May 2026 |
| Margin Keuntungan | -29.95% |
| Margin Operasi (TTM) | -25.97% |
| EPS Cair (TTM) | -1.18 |
| Pertumbuhan Hasil Suku Tahunan (YOY) | 107.50% |
| Jumlah Hutang/Ekuiti (D/E MRQ) | 35.65% |
| Nisbah Semasa (MRQ) | 5.20 |
| Aliran Tunai Operasi (OCF TTM) | -263.30 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | -202.32 M |
| Pulangan Atas Aset (ROA TTM) | -8.77% |
| Pulangan Atas Ekuiti (ROE TTM) | -20.00% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Biotechnology (US) | Menaik | Bercampur |
| Biotechnology (Global) | Menaik | Bercampur | |
| Stok | Legend Biotech Corporation | Menurun | Menurun |
AISkor Stockmoo
| Konsensus Penganalisis | 3.0 |
| Aktiviti Orang Dalam | NA |
| Volatiliti Harga | -1.0 |
| Purata Bergerak Teknikal | 0.0 |
| Osilator Teknikal | 2.0 |
| Purata | 1.00 |
|
Legend Biotech Corp is a clinical-stage biopharmaceutical company. It is engaged in the discovery and development of novel cell therapies for oncology and other indications. The firm's product candidate, LCAR-B38M/JNJ-4528, is a chimeric antigen receptor, or CAR, T cell therapy for the treatment of multiple myeloma. Geographically, the company generates a majority of its revenue from the United States of America. The company generates revenue from License and Collaboration revenue. |
|
| Sektor | Healthcare |
| Industri | Biotechnology |
| % Dimiliki oleh Orang Dalam | 1.31% |
| % Dimiliki oleh Institusi | 47.92% |
Pemilikan
| Nama | Tarikh | Syer Dipegang |
|---|---|---|
| Hhlr Advisors, Ltd. | 31 Dec 2025 | 5,984,550 |
| Davern Capital Partners, Lp | 31 Dec 2025 | 1,056,668 |
| Matthews International Capital Management Llc | 31 Dec 2025 | 956,824 |
| Julat 52 Minggu | ||
| Julat Harga Sasaran | ||
| Tinggi | 80.00 (Barclays, 239.13%) | Beli |
| Median | 62.00 (162.82%) | |
| Rendah | 49.00 (Morgan Stanley, 107.72%) | Beli |
| Purata | 63.67 (169.90%) | |
| Jumlah | 3 Beli | |
| Harga Purata @ Panggilan | 19.06 | |
| Syarikat | Tarikh | Harga Sasaran | Panggilan | Harga @ Panggilan |
|---|---|---|---|---|
| Morgan Stanley | 11 Mar 2026 | 49.00 (107.72%) | Beli | 20.27 |
| RBC Capital | 11 Mar 2026 | 62.00 (162.82%) | Beli | 20.27 |
| Barclays | 04 Feb 2026 | 80.00 (239.13%) | Beli | 16.65 |
Tiada data dalam julat masa ini.
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2026 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |